NATCO Pharma quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	735	1,329	−44.7%
EBITDA	187	571	−67.3%
EBITDA margin	25.4%	43.0%	−17.6 pts
Profit before tax	186	572	−67.5%
Net profit	207	480	−57.0%
EPS	₹11.53	₹26.84	−57.0%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	735	739	647	1,363	1,329	1,221	475	1,371	1,363	1,068	759	1,031	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	59.2	77.8	58.1	100	61.7	66.3	176	63.8	48.1	42.0	37.0	29.4
	794	817	705	1,463	1,391	1,287	651	1,435	1,411	1,110	796	1,061
	158	103	135	175	181	169	72.7	143	151	128	92.2	167
	27.8	37.5	55.8	72.6	37.3	40.8	39.1	53.7	32.5	31.1	36.7	41.0
	−38.1	14.4	−57.9	−77.8	15.1	39.4	−29.0	−19.3	−3.6	−16.1	33.3	8.3
	179	159	159	200	169	159	142	152	142	143	122	122
	13.0	10.9	9.5	13.1	3.2	10.2	4.4	4.1	5.2	6.2	4.6	4.2
	47.1	50.4	46.2	52.4	57.6	98.3	47.0	45.8	44.1	55.5	44.2	43.6
	222	298	196	414	356	264	212	238	236	286	206	235
	609	673	544	849	819	781	487	617	607	633	539	621
	187	128	159	579	571	548	38.8	804	805	497	268	458
	139	77.2	113	527	513	450	−8.2	759	761	442	224	414
Profit
	186	144	161	614	572	506	164	818	804	478	256	440
	186	144	161	614	572	506	164	818	804	478	256	440
	48.8	16.1	31.3	140	116	106	33.5	154	144	90.3	52.2	81.9
	14.6	−105	−10.6	−44.6	−24.1	−6.5	−2.2	−12.4	−8.5	1.0	−8.6	−11.3
	63.4	−89.2	20.7	95.8	91.6	99.9	31.3	142	135	91.3	43.6	70.6
	84.3	35.7	10.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	207	269	151	518	480	406	132	677	669	386	213	369
	122	233	140	518	480	406	132	677	669	386	213	369
	111	83.2	125	40.4	39.3	−18.2	−10.6	19.2	−14.4	−12.5	17.9	−4.8
	318	352	276	558	520	388	122	696	654	374	231	364
	207	268	152	518	481	407	133	677	669	386	213	369
	0.0	1.1	−0.2	−0.5	−0.4	−0.6	−0.6	−0.8	0.0	0.0	0.0	0.0
Per share
	₹11.53	₹14.96	₹8.46	₹28.94	₹26.84	₹22.70	₹7.43	₹37.81	₹37.32	₹21.56	₹11.88	₹20.60
	₹11.53	₹14.96	₹8.46	₹28.94	₹26.84	₹22.70	₹7.43	₹37.81	₹37.32	₹21.56	₹11.88	₹20.60
Other comprehensive income — detail
	111	83.2	125	40.4	39.3	−18.2	—	—	—	—	—	—
	8.9	13.8	7.1	14.8	4.6	−25.3	15.4	4.3	2.2	−1.8	2.8	2.5
	—	—	—	—	—	—	0.0	−14.9	0.0	0.0	0.3	0.3
	102	69.4	117	25.6	34.7	7.1	−26.0	0.0	−16.6	−10.7	15.4	−7.0
	318	351	276	559	520	388	122	697	654	374	231	364
	0.0	1.1	−0.2	−0.5	−0.4	−0.6	−0.6	−0.8	0.0	0.0	0.0	0.0
Per share — as-filed variants
	₹11.53	₹14.96	₹8.46	₹28.94	₹26.84	₹22.70	₹7.43	₹37.81	₹37.32	₹21.56	₹11.88	₹20.60
	₹11.53	₹14.96	₹8.46	₹28.94	₹26.84	₹22.70	₹7.43	₹37.81	₹37.32	₹21.56	₹11.88	₹20.60
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	588	584	514	1,193	1,096	972	392	1,194	1,182	926	596	816
	79.9%	79.1%	79.4%	87.5%	82.5%	79.6%	82.6%	87.0%	86.8%	86.7%	78.6%	79.1%
Adjusted (ex-exceptional items) — derived
	186	144	161	614	572	506	164	818	804	478	256	440
	207	269	151	518	480	406	132	677	669	386	213	369
	₹11.53	₹14.96	₹8.46	₹28.94	₹26.84	₹22.70	₹7.43	₹37.81	₹37.32	₹21.56	₹11.88	₹20.60

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NATCOPHARM₹793.00

NATCO Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDRREDDY ZYDUSLIFE SUNPHARMA LALPATHLAB NEULANDLAB NH SAILIFE COHANCEMcap ₹14,195 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,031.4	758.6	1,068.3	1,362.6	1,371.1	474.8	1,221.0	1,328.9	1,363.0	647.3	739.1	735.2
Other Income	29.4	37.0	42.0	48.1	63.8	176.3	66.3	61.7	100.0	58.1	77.8	59.2
Total Income	1,060.8	795.6	1,110.3	1,410.7	1,434.9	651.1	1,287.3	1,390.6	1,463.0	705.4	816.9	794.4
Expenses
+ Cost of Materials Consumed	166.5	92.2	127.6	151.3	143.2	72.7	169.0	180.6	174.9	135.2	102.8	157.8
+ Purchases of Stock-in-Trade	41.0	36.7	31.1	32.5	53.7	39.1	40.8	37.3	72.6	55.8	37.5	27.8
+ Changes in Inventories	8.3	33.3	-16.1	-3.6	-19.3	-29.0	39.4	15.1	-77.8	-57.9	14.4	-38.1
+ Employee Benefit Expense	122.4	121.9	142.5	142.0	151.5	141.6	159.4	169.0	200.3	159.4	158.5	179.3
+ Finance Costs	4.2	4.6	6.2	5.2	4.1	4.4	10.2	3.2	13.1	9.5	10.9	13.0
+ Depreciation & Amortisation	43.6	44.2	55.5	44.1	45.8	47.0	98.3	57.6	52.4	46.2	50.4	47.1
+ Other Expenses	235.2	206.4	285.9	235.6	237.7	211.6	264.3	355.9	413.8	196.1	298.3	221.9
Total Expenses	621.2	539.3	632.7	607.1	616.7	487.4	781.4	818.7	849.3	544.3	672.8	608.8
EBITDA	458.0	268.1	497.3	804.8	804.3	38.8	548.1	571.0	579.2	158.7	127.6	186.5
EBIT	414.4	223.9	441.8	760.7	758.5	-8.2	449.8	513.4	526.8	112.5	77.2	139.4
Profit
PBT before Exceptional Items	439.6	256.3	477.6	803.6	818.2	163.7	505.9	571.9	613.7	161.1	144.1	185.6
Pretax Income	439.6	256.3	477.6	803.6	818.2	163.7	505.9	571.9	613.7	161.1	144.1	185.6
+ Current Tax	81.9	52.2	90.3	143.6	154.1	33.5	106.4	115.7	140.4	31.3	16.1	48.8
+ Deferred Tax	-11.3	-8.6	1.0	-8.5	-12.4	-2.2	-6.5	-24.1	-44.6	-10.6	-105.3	14.6
Tax Expense	70.6	43.6	91.3	135.1	141.7	31.3	99.9	91.6	95.8	20.7	-89.2	63.4
+ Share of Associates & JVs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.9	35.7	84.3
Net Income	369.0	212.7	386.3	668.5	676.5	132.4	406.0	480.3	517.9	151.3	269.0	206.5
+ Net Income — Continuing Ops	369.0	212.7	386.3	668.5	676.5	132.4	406.0	480.3	517.9	140.4	233.3	122.2
+ Other Comprehensive Income	-4.8	17.9	-12.5	-14.4	19.2	-10.6	-18.2	39.3	40.4	124.5	83.2	111.0
Total Comprehensive Income	364.2	230.6	373.8	654.1	695.7	121.8	387.8	519.6	558.3	275.8	352.2	317.5
Net Income to Common	369.0	212.7	386.3	668.5	677.3	133.0	406.6	480.7	518.4	151.5	267.9	206.5
Minority Interest	0.0	0.0	0.0	0.0	-0.8	-0.6	-0.6	-0.4	-0.5	-0.2	1.1	0.0
Per Share
Basic EPS	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Diluted EPS	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-18.2	39.3	40.4	124.5	83.2	111.0
+ Items NOT to be Reclassified to P&L	2.5	2.8	-1.8	2.2	4.3	15.4	-25.3	4.6	14.8	7.1	13.8	8.9
+ Tax on Items NOT to be Reclassified — alt tag	0.3	0.3	0.0	0.0	-14.9	0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-7.0	15.4	-10.7	-16.6	0.0	-26.0	7.1	34.7	25.6	117.4	69.4	102.1
Comprehensive Income — Owners of Parent	364.2	230.6	373.8	654.1	696.5	122.4	388.4	520.0	558.8	276.0	351.1	317.5
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	0.0	-0.8	-0.6	-0.6	-0.4	-0.5	-0.2	1.1	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Diluted EPS — Continuing Operations	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	815.6	596.4	925.7	1,182.4	1,193.5	392.0	971.8	1,095.9	1,193.3	514.2	584.4	587.7
Gross Margin %	79.08	78.62	86.65	86.78	87.05	82.56	79.59	82.47	87.55	79.44	79.07	79.94
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	439.6	256.3	477.6	803.6	818.2	163.7	505.9	571.9	613.7	161.1	144.1	185.6
Net Income Adj (tax-effected)	369.0	212.7	386.3	668.5	676.5	132.4	406.0	480.3	517.9	151.3	269.0	206.5
EPS Adj	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	35.8	35.8	35.8	35.8	35.8	35.8	35.8	35.8	35.8	35.8	35.8	35.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

NATCO Pharma Q2 FY27 results date

NATCO Pharma (NSE: NATCOPHARM) will announce its Q2 FY27 results (July–September 2026) on Friday, 13 November 2026, according to the board-meeting notice it filed on 29 October 2026, which also lists a dividend. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹207 crore, down 57.0% from ₹481 crore in Q1 FY26 and down 22.9% from ₹268 crore in Q4 FY26. Revenue from operations was ₹735 crore, down 44.7% year on year and down 0.5% from the previous quarter.

Board-meeting notice filed: 29 October 2026
Q1 FY27 results (the latest): 14 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 13 November 2026Friday · notice filed 29 Oct
Q1 FY27 net profit: ₹207 Cr−57.0% vs Q1 FY26−22.9% vs Q4 FY26
Q1 FY27 revenue: ₹735 Cr−44.7% vs Q1 FY26−0.5% vs Q4 FY26
Q1 FY27 operating margin: 19.0%−19.7 pts vs Q1 FY26+8.5 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹518 CrRevenue ₹1,363 Cr
Q1 FY27 EPS (basic): ₹11.53

Questions

When will NATCO Pharma announce its Q2 FY27 results?

On 13 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 29 October 2026).

What was NATCO Pharma's net profit in FY26?

Consolidated net profit was ₹1,419 crore in FY26 (April 2025–March 2026), down 24.8% from ₹1,885 crore in FY25. It was ₹1,388 crore in FY24 and ₹715 crore in FY23: up 98.3% over three years, 25.6% a year on average.

What was NATCO Pharma's revenue in FY26?

Revenue from operations was ₹4,078 crore in FY26 (April 2025–March 2026), down 7.9% from ₹4,430 crore in FY25. It was ₹3,999 crore in FY24 and ₹2,707 crore in FY23: up 50.7% over three years, 14.6% a year on average.

What will NATCO Pharma's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹518 crore and revenue from operations ₹1,363 crore. The latest quarter, Q1 FY27, had a net profit of ₹207 crore and revenue of ₹735 crore.

What were NATCO Pharma's Q1 FY27 results?

Consolidated net profit was ₹207 crore, down 57.0% from ₹481 crore in Q1 FY26 and down 22.9% from ₹268 crore in Q4 FY26. Revenue from operations was ₹735 crore, down 44.7% year on year and down 0.5% from the previous quarter.

How has NATCO Pharma's profit changed over the last four quarters?

Net profit by quarter: ₹518 crore in Q2 FY26, ₹152 crore in Q3 FY26, ₹268 crore in Q4 FY26 and ₹207 crore in Q1 FY27. That is ₹1,144 crore over the four quarters, down 32.6% from ₹1,698 crore in the four quarters before. Revenue from operations: ₹1,363 crore, ₹647 crore, ₹739 crore and ₹735 crore.

Where do these NATCO Pharma figures come from?

From NATCO Pharma's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.